

11-4-2017

# The Arabidopsis thaliana lysophospholipid acyltransferase At1g78690p acylates lysocardiolipins

Reuben M. Moncada  
*Vassar College*

Katherine J. Blackshear  
*Vassar College*

Teresa A. Garrett  
*Vassar College*

Follow this and additional works at: [https://digitalwindow.vassar.edu/faculty\\_research\\_reports](https://digitalwindow.vassar.edu/faculty_research_reports)



Part of the [Biochemistry, Biophysics, and Structural Biology Commons](#)

---

## Citation Information

Moncada, Reuben M.; Blackshear, Katherine J.; and Garrett, Teresa A., "The Arabidopsis thaliana lysophospholipid acyltransferase At1g78690p acylates lysocardiolipins" (2017). *Faculty Research and Reports*. 114.  
[https://digitalwindow.vassar.edu/faculty\\_research\\_reports/114](https://digitalwindow.vassar.edu/faculty_research_reports/114)

This Article is brought to you for free and open access by Digital Window @ Vassar. It has been accepted for inclusion in Faculty Research and Reports by an authorized administrator of Digital Window @ Vassar. For more information, please contact [library\\_thesis@vassar.edu](mailto:library_thesis@vassar.edu).

# The *Arabidopsis thaliana* lysophospholipid acyltransferase

## At1g78690p acylates lysocardiolipins

Reuben M. Moncada<sup>1</sup>, Katherine J. Blackshear<sup>1</sup>, and Teresa A. Garrett<sup>1\*</sup>

<sup>1</sup>Department of Chemistry, Vassar College, 124 Raymond Avenue, Poughkeepsie, NY 12604

\*To whom correspondence should be addressed

email: [tegarrett@vassar.edu](mailto:tegarrett@vassar.edu)

Phone: 845-437-5738

Fax: 845-437-5747

**Keywords:** Lysophospholipid acyltransferase, cardiolipin, monolysocardiolipin, acyl-phosphatidylglycerol

## **Abbreviations**

LC-MS - liquid chromatography mass spectrometry

GPL - glycerophospholipid

acyl PG - acyl phosphatidylglycerol

PC - phosphatidylcholine

PS - phosphatidylserine

PI - phosphatidylinositol

PE - phosphatidylethanolamine

BMP - bis(monoacylglycerol)phosphate

CL - cardiolipin

MLCL - monolyso cardiolipin

DLCL - dilyso cardiolipin

LPLAT - lysophospholipid acyltransferases

AGPAT - 1-acyl-glycerol-3-phosphate O-acyltransferase (AGPAT)

## Abstract

The *Arabidopsis thaliana* lysophospholipid acyltransferase At1g78690 acylates a variety of lysophospholipids such as lyso phosphatidylglycerol, lyso phosphatidylethanolamine and lyso phosphatidylserine. Despite di-acylate phosphatidylglycerol being a substrate, overexpression of At1g78690 in *Escherichia coli* leads to the accumulation of acyl-PG. Here we show that cardiolipin also accumulates in cells overexpressing At1g78690. To help try and explain this observation, we show, using a liquid chromatography mass spectrometry (LC-MS) based assay, that At1g78690 utilizes both mono- and di-lyso cardiolipin as an acyl acceptor. Because At1g78690 shares high homology (~40%) with the cardiolipin remodeling enzyme tafazzin, we also tested whether At1g78690 was able to catalyze a tafazzin-like transacylation reaction. Di-linoleoyl phosphatidylcholine was used as the acyl donor and mono-lyso cardiolipin was used as the acyl acceptor in a reaction and the reaction was monitored by LC-MS. No transfer of the linoleoyl chains was detected in an At1g78690 dependent manner suggesting that, despite the strong homology, these enzymes catalyze unique reactions.

## Introduction

The *Arabidopsis thaliana* gene At1g78690 encodes a lysophospholipid acyltransferase that utilizes acyl-CoA to acylate mono-acylated glycerophospholipids (GPLs) to their di-acylated GPLs *in vitro* [1, 2] yet when it is overexpressed in *Escherichia coli* the headgroup acylated GPL acyl phosphatidylglycerol (acyl PG) accumulates. At1g78690 does not, however, acylate the headgroup of PG directly [1]. Recently we have shown that At1g78690 also acylates *bis*(monoacylglycero)phosphate (BMP) to form acyl-PG [2]. This activity potentially explains the accumulation of acyl PG in *E. coli* when At1g78690 is overexpressed *in vivo* – endogenous BMP found in *E. coli* is acylated to acyl PG *in vivo* leading to increased levels of acyl PG.

At1g78690's closest protein homolog is the transacylase tafazzin [3]. Tafazzin has been implicated in remodeling cardiolipin, a tetra-acylated GPL [4, 5]. A mutation in the gene encoding for tafazzin, leads to an X-linked cardiomyopathy known as Barth's syndrome [6-8]. Cells deficient in tafazzin have a decreased levels of cardiolipin (CL) and elevated levels of monolysocardiolipin (MLCL), allowing MLCL/CL ratios to serve as a diagnostic tool for Barth's syndrome [4].

As related above, tafazzin is involved in the remodeling of the cardiolipin acyl chains, converting *de novo* synthesized CL to primarily tetralinoleoyl CL [9]. Tafazzin catalyzes the acylation of lyso phosphatidylcholine (lyso PC) from acyl chains derived from tetra-acylated CL, and also catalyzes the reverse reaction, acylating MLCL from acyl chains derived from PC. Tafazzin displays broad acyl chain specificity under certain *in vitro* conditions [5, 10], however, promotes specific remodeling of CL to tetralinoleoyl CL in the context of non-bilayer lipid membranes [11].

At1g78690 shares 39% and 41% sequence homology to human and *Drosophila melanogaster* tafazzins, respectively, indicative of a shared fold and enzymatic mechanism. Indeed, At1g78690 is likely the *A. thaliana* version of tafazzin and suggests that At1g78690 may possess tafazzin-like activity or play a role in modulating CL composition *in vivo*.

In eukaryotes, CL is found in the inner mitochondrial membrane in eukaryotes and is critical for mitochondrial function [12]. It serves as a necessary proton trap for oxidative phosphorylation and is a trigger for apoptosis. In bacteria such as *E. coli*, CL is also enriched at the cell poles and cell division sites [13, 14] and is involved in the osmotic stress response[15].

Here we show that expression of At1g78690 impacts the levels of CL in *E. coli* in addition to the acyl-PG levels. In addition, because of the high homology of At1g78690 to tafazzin we investigated the enzyme's ability to acylate MLCL and DLCL as well as whether At1g78690 possesses tafazzin-like MLCL:PC transacylase activity.

## 2. Materials and Methods

### 2.1 Materials

Solvents for lipid extraction were reagent grade from Sigma. High performance liquid chromatography solvents were CHROMASOLV® Plus, HPLC grade from Sigma Aldrich. Other chemicals were purchased from VWR or Sigma–Aldrich.

Heart bovine monolysocardiolipin (MLCL), dilyocardiolipin (DLCL), 1,2-dilinoleoyl-*sn*-glycero-3-phosphocholine (18:2 PC), and 20:5-Coenzyme A were from Avanti Polar Lipids (Alabaster, AL).

### 2.1 Growth of *E. coli* and preparation of protein extracts

*E. coli* BLR(DE3)pLysS were transformed with pET15b and pHis-AT1g78690Lipid and grown as described previously [1]. Following harvesting by centrifugation for 20 minutes at 2600 x g, cell pellets were washed with 15 mM Tris, pH 7.4 and the centrifugation repeated to harvest cells. Cell pellets were frozen at -80 °C until further use.

Cell-free extracts and membranes were prepared as described previously [2]. Protein concentrations were determined using a bicinchoninic acid reagent (Thermo Scientific) with bovine serum albumin as the standard. All protein samples were stored at -80 °C until needed.

### 2.2 Preparation of *in vitro* enzyme products

*In vitro* products were generated in a 0.5 ml reaction that contained 100 μM 20:4 or 20:5-CoA, 300 μM acyl acceptor (MLCL, DLCL, or 1-acyl lyso GPL), 15 mM Tris pH 7.4, and 0.05% Triton X-100, and were initiated by the addition of 0.5 mg/mL membranes from BLR(DE3)pLysS/pET15b or BLR(DE3)pLysS/pHis-At1g78690 prepared as described previously [2]. For transacylation assays, 100 μM di-linoleoyl PC was included in place of the acyl CoA, and 300 μM MLCL as the acyl acceptor. Reactions were incubated at 37°C for 3

hours and terminated by Bligh-Dyer extraction [2, 16]. The lower phase of the two-phase system was transferred to a glass vial equipped with a glass volume reducer, dried under a stream of N<sub>2</sub> gas and stored at -20°C until analysis.

### *2.3 Mass spectrometry of in vitro products*

The dried products from each *in vitro* acylation or transacylation reaction was re-suspended in 100 µL CHCl<sub>3</sub>:CH<sub>3</sub>OH (2:1 v/v) and analyzed using normal phase liquid chromatography electrospray ionization quadrupole time-of-flight mass spectrometer as described previously [2].

### 3. Results

#### 3.1 Overexpression of *At1g78690* leads to the accumulation of CL in addition to acyl PG.

Previously we have shown that overexpression of *At1g78690* leads to the accumulation of the headgroup acylated GPL acyl PG [1]. Further examination of the LC-MS profile reveals that, in addition, a number of cardiolipin species accumulate. Figure 1 shows that the total amount of cardiolipin increases in lipid extracts derived from BLR(DE3)pLysS cells expressing *At1g78690* compared to lipid extracts prepared from cells expressing pET vector alone. Based on the  $m/z$  of the CLs, the CLs range from CL with 62:1 (total carbons:total unsaturations in the acyl chains) at  $m/z$  1321.919 to 70:3 at  $m/z$  1430.003.

#### 3.2 MLCL and DLCL acylation

*At1g78690* robustly acylates 1-acyl lyso phosphatidylethanolamine (PE), 1-acyl lyso PG, 1-acyl lyso phosphatidylserine (PS), and 1-acyl phosphatidylinositol (PI) using acyl-CoA as the acyl donor to produce PE, PG, PS, and PI, respectively [1, 2]. Since heterologous expression of *At1g78690* in *E. coli* impacts the lipid profile by altering CL levels, and because *At1g78690* has been shown to acylate various lysophospholipids, we hypothesized that *At1g78690* may be acylating endogenous under-acylated CLs to form CL. Using a LC-MS based assay, we assessed whether *At1g78690* can catalyze the acylation of DLCL to form MLCL, and if *At1g78690* can acylate MLCL to CL. Using 20:5 acyl-CoA as the acyl donor and MLCL or DLCL as the acyl acceptor we monitored the formation of the expected products using membranes prepared from cells expressing *At1g78690*, and compare these products to those formed from the reaction using membranes expressing vector alone. For both acyl acceptors, MLCL and DLCL, both of which are predominantly acylated with

linoleate (18:2), the expected acylated products CL and MLCL were detected (Figure 2). In Panel A, the  $[M-H^+]$  at  $m/z$  1469.972 corresponds to the expected CL product with three 18:2 chains and a fourth 20:5 chain added by At1g78690. In Panel B, the  $[M-2H^+]^2$  at  $m/z$  603.365 corresponds to the expected MLCL product with two 18:2 chains and a third 20:5 chain added by At1g78690.

### 3.3 MLCL:PC transacylation

Tafazzin has been shown to have phospholipid transacylase activity, capable of transferring the acyl chain from PC to acylate MLCL, forming CL and lyso PC [3-5]. Using a similar LC-MS based assay, we tested for tafazzin-like transacylase activity in membranes with At1g78690 as the enzyme source. Using MLCL as the acyl acceptor and 18:2 PC as the acyl donor, we monitored the incorporation of linoleoylate into CL and other GPLs. No CLs with  $m/z$ 's consistent with 18:2 acyl chains incorporation were detected in an At1g78690- or PC-dependent manner. Figure 3 shows the region of the negative ion MS where the expected CL ion ( $m/z$  1447.9649) would be present. There was no detectable difference in the levels of this ion in the absence or presence of At1g78690 (Panels B and C compared to D and E). The presence of PC did not impact the level of the ion at  $m/z$  1447.965. The CL at  $m/z$  1447.965 that is detected is derived from the MLCL (compare Panel A where no MLCL was added to Panel B).

Careful review of the MS data showed that no 18:2 acyl chains were detected in other phospholipid pools in an At1g78690 dependent manner. Taken together this data suggests that At1g78690 does not function as a transacylase using PC as an acyl donor.

#### 4. Discussion

Lysophospholipid acyltransferases (LPLAT) within the 1-acyl-glycerol-3-phosphate O-acyltransferase (AGPAT) family [17, 18], such as At1g78690 are necessary for generating membrane lipid diversity through the Land's cycle remodeling pathway and through *de novo* biosynthesis in the Kennedy pathway [19]. When the acyl-CoA dependent LPLAT At1g78690 is overexpressed in *E. coli*, the lipid profile is altered through increased levels of CL in addition to an increase in the headgroup acylated GPL acyl PG. Currently we hypothesize that At1g78690 is leading to increased levels of acyl PG because of its ability to acylate bis-(monoacylglycerol) phosphate (BMP) [2] and to a small extent, the headgroup of lyso PG [20]. The sequential acylation of lysoPG to BMP and then BMP to acyl PG may explain the accumulation of acyl PG despite At1g78690 not effectively acylating the *sn*-2 position of PG [1].

The increase in CL was particularly intriguing given the high homology At1g78690 shares with tafazzin [3, 4]. Despite this, At1g78690 does not appear to catalyze similar transacylation reactions. When At1g78690 was provided di-linoleoyl PC as a substrate from which to serve as any acyl donor to MLCL, the predicted product was not detected. In addition, careful review of the data showed that no other lipids contained the 18:2 acyl chains from di-linoleoyl PC in an At1g78690 dependent manner.

Recent work with tafazzin suggests that its ability to preferentially transfer 18:2 acyl chains into MLCL is dependent on lipid structural order. When the lipid substrates are present in non-bilayer lipid membranes there is a strong preference for linoleoyl acyl chains compared to oleoyl acyl chains. The impact of the lipid environment on At1g78690 remains to be investigated directly. However, the major GPL of *E. coli* inner membranes,

where At1g78690 is presumed to be located as a peripheral membrane protein, is mainly composed of PE [21], a non-bilayer forming lipid [22]. This suggests that the membrane environment would be suitable for At1g78690 to display tafazzin-like transacylation reactions.

The increase in CL levels observed due to At1g78690 expression may, at least in part, be the result of endogenous lyso CL acylation by At1g78690 to form CL. Cardiolipin has been noted for its role in the binding and regulation of peripheral membrane proteins in bacteria [23]. Since At1g78690 is a peripheral membrane protein, it is possible that At1g78690 expression stimulates CL biosynthesis in order for At1g78690 to be properly localized within the membrane; it remains to be investigated whether or not CL is necessary for At1g78690 function and localization in the membrane.

The increase in CL may also be in response to the lipid composition changes that occur following At1g78690 expression. The depletion of lyso-GPLs that may occur due to At1g78690 activity may lead to disruptions of the lipid bilayer inducing compensatory increases in CL. Lyso-GPLs have been shown to behave similarly to detergents with the ability to disrupt bilayers [24]. The increase in CL may somehow be fortifying the membrane in the presence of At1g78690 induced lipid composition changes.

Previously it has been shown that CL can accumulate upon overexpression of certain membrane proteins [23, 25-27]. For example, overexpression of the F-ATPase subunit b leads to the formation of intracellular cytoplasmic membranes (ICMs) that resemble mitochondrial inner cristae [25, 28]. It remains to be determined whether cells overexpressing At1g78690 also possess ICMs.

## **Acknowledgements**

This work was supported by National Science Foundation – Research at Undergraduate Institution grant #1516805 and Major Research Instrumentation grant #1039659 to T. A.

G.

## Figure Legends

Figure 1: **Cardiolipin accumulates when At1g78690 is overexpressed in *E. coli*.** Total lipid extracts were prepared from IPTG-induced BLR(DE3)pLysS/pET15b and BLR(DE3)pLysS/pHis-At1g78690 and analyzed using LC/ESI-MS. The negative ion spectra from  $m/z$  1320 to 1430 of the material eluting between minutes 18 and 20 of the normal phase chromatography are shown. The labeled ions correspond to  $[M-H^+]$  ions of CL.

Figure 2: **At1g78690 can acylate MLCL and DLCL.** Membranes from IPTG-induced BLR(DE3)pLysS/pET15b and BLR(DE3)pLysS/pHis-At1g78690 were used as the enzyme source in an *in vitro* assay using 20:5-CoA as the acyl donor and MLCL (Panel A) or DLCL (Panel B) as the acyl acceptor. The lipids from each reaction mixture were extracted and analyzed using LC/ESI-MS. The negative-ion mass spectrum of the  $m/z$  region for the expected products are shown. The expected ion using MLCL as the acyl acceptor ( $[M-H^+]$ ,  $m/z$  1469.9) was formed at higher levels when At1g78690 was present (Panel A). The expected ion using DLCL as the acyl acceptor ( $[M-2H^+]^2$ ,  $m/z$  603.3) also was formed at higher levels only when At1g78690 was present in the membranes.

Figure 3: **At1g78690 does not catalyze a tafazzin-like PC:MLCL transacylation reaction.** Membranes from BLR(DE3)pLysS/pET15b and BLR(DE3)pLysS/pHis-At1g78690 were used as the enzyme source in an *in vitro* assay using 18:2 PC and MLCL as the acyl donor and the acyl acceptor, respectively. Following incubation, lipids were extracted and then analyzed using LC/ESI-MS. The negative ion spectrum of the material eluting between minutes 18 and 20 are shown. For Panels A, B, and C and Panels D and E

membranes from BLR(DE3)pLysS/pET15b or from BLR(DE3)pLysS/p His-At1g78690, respectively were used as the enzyme source with the following combinations of acyl donors and acceptors: 18:2 PC but no MLCL (Panel A), MLCL but no 18:2 PC (Panel B and D), MLCL and 18:2 PC (Panel C and E).

## References

- [1] E. Bulat, T.A. Garrett, Putative *N*-acylphosphatidylethanolamine synthase from *Arabidopsis thaliana* is a lysoglycerophospholipid acyltransferase., *The Journal of Biological Chemistry*, 286 (2011) 33819-33831.
- [2] T.A. Garrett, R.M. Moncada, The *Arabidopsis thaliana* lysophospholipid acyltransferase At1g78690p acylates a variety of lysophospholipids including *bis*(monoacylglycero)phosphate., *Biochemical and Biophysical Research Communications*, 452 (2014) 1022-1027.
- [3] M. Schlame, Cardiolipin remodeling and the function of tafazzin, *Biochimica et Biophysica Acta*, 1831 (2013) 582-588.
- [4] R.H. Houtkooper, M. Turkenburg, B.T. Poll-The, D. Karall, C. Pérez-Cerdá, A. Morrone, S. Malvagia, R.J. Wanders, W. Kulik, F.M. Vaz, The enigmatic role of tafazzin in cardiolipin metabolism, *Biochimica et Biophysica Acta - Biomembranes*, 1788 (2009) 2003-2014.
- [5] Y. Xu, A. Malhotra, M. Ren, M. Schlame, The Enzymatic Function of Tafazzin, *Journal of Biological Chemistry*, 281 (2006) 39217-39224.
- [6] R.O.I. Ryan, N., Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy, *Lipids*, 52 (2017) 99-108.
- [7] K.D. Hauff, G.M. Hatch, Cardiolipin metabolism and Barth Syndrome, *Progress in Lipid Research*, 45 (2006) 91-101.
- [8] S.M. Claypool, J.M. McCaffery, C.M. Koehler, Mitochondrial mislocalization and altered assembly of a cluster of Barth syndrome mutant tafazzins., *Journal of Cell Biology*, 174 (2006) 379-390.

- [9] M.T. Schlame, J.A.; Heerdt, P.M.; Jehle, R.; DiMauro, S.; Blanck, T.J.J., Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome, *Annals of Neurology*, 51 (2002) 634-637.
- [10] Y. Xu, R.I. Kelley, T.J. Blanck, M. Schlame, Remodeling of cardiolipin by phospholipid transacylation, *Journal of Biological Chemistry*, 278 (2003) 51380-51385.
- [11] M. Schlame, D. Acehan, B. Berno, Y. Xu, S. Valvo, M. Ren, D.L. Stokes, R.M. Epanand, The physical state of lipid substrates provides transacylation specificity for tafazzin, *Nature Chemical Biology*, 8 (2012) 862-869.
- [12] M. Schlame, D. Rua, M.L. Greenberg, The biosynthesis and functional role of cardiolipin, *Progress in lipid research*, 39 (2000) 257-288.
- [13] E. Mileykovskaya, W. Dowhan, Cardiolipin membrane domains in prokaryotes and eukaryotes, *Biochimica et Biophysica Acta - Biomembranes*, 1788 (2009) 2084-2091.
- [14] C.-M. Koppelman, T. den Blaauwen, M.C. Duursma, R.M.A. Heeren, N. Nanninga, *Escherichia coli* minicell membranes are enriched in cardiolipin, *Journal of Bacteriology*, 183 (2001) 6144-6147.
- [15] T. Romantsov, L. Stalker, D.E. Culham, J.M. Wood, Cardiolipin controls the osmotic stress response and the subcellular location of transporter ProP in *Escherichia coli*, *Journal of Biological Chemistry*, 283 (2008) 12314-12323.
- [16] E.G. Bligh, W.J. Dyer, A rapid method of total lipid extraction and purification., *Canadian Journal of Biochemistry and Physiology*, 37 (1959) 911-917.
- [17] H. Shindou, T. Shimizu, Acyl-CoA:lysophospholipid acyltransferases, *Journal of Biological Chemistry*, 284 (2009) 1-5.

- [18] H. Shindou, D. Hishikawa, T. Harayama, K. Yuki, T. Shimizu, Recent progress on acyl CoA: lysophospholipid acyltransferase research., *Journal of lipid research*, 50 Suppl (2009) S46-51.
- [19] H. Shindou, D. Hishikawa, T. Harayama, M. Eto, T. Shimizu, Generation of membrane diversity by lysophospholipid acyltransferases, *Journal of Biochemistry*, 154 (2013) 21-29.
- [20] T.A. Garrett, G. Isaac, Bis(monoacylglycero)phosphate is a product of the *Arabidopsis thaliana* lysoglycerophospholipid acyltransferase., *Analytical Biochemistry*, Submitted (2017).
- [21] R.E. Bishop, Emerging roles for anionic non-bilayer phospholipids in fortifying the outer membrane permeability barrier, *Journal of Bacteriology*, 196 (2014) 3209-3213.
- [22] W. Dowhan, A retrospective: use of *Escherichia coli* as a vehicle to study phospholipid synthesis and function, *Biochimica et Biophysica Acta*, 1831 (2013) 471-494.
- [23] P.M. Oliver, J.A. Crooks, M. Leidl, E.J. Yoon, A. Saphatelian, D.B. Weibel, Localization of anionic phospholipids in *Escherichia coli* cells., *Journal of Bacteriology*., 196 (2014) 3386-3398.
- [24] C.E. Creutz, J.K. Hira, V.E. Gee, J.M. Eaton, Protection of the membrane permeability barrier by annexins., *Biochemistry*, 51 (2012) 9966-9983.
- [25] G. Carranza, F. Angius, O. Illoaia, A. Solgadi, B. Miroux, I. Arechaga, Cardiolipin plays an essential role in the formation of intracellular membranes in *Escherichia coli*, *Biochimica et Biophysica Acta*, 1859 (2017).
- [26] L.D. Renner, D.B. Weibel, MinD and MinE interact with anionic phospholipids and regulate division plane formation in *Escherichia coli* ., *Journal of Biological Chemistry*, 287 (2012) 38835-38844.

[27] R. Arias-Cartin, S. Grimaldi, P. Arnoux, B. Guigliarelli, A. Magalon, Cardiolipin binding in bacterial respiratory complexes: Structural and functional implications. , *Biochimica et Biophysica Acta - Bioenergetics*, 1817 (2012) 1937-1949.

[28] I. Arechaga, B. Miroux, S. Karrasch, R. Huijbregts, B. deKruijff, J. Runswick, J.E. Walker, Characterization of new intracellular membranes in *Escherichia coli* accompanying large scale over-production of the b subunit of the F1F0 ATP synthase, *FEBS Letters*, 482 (2000) 215-219.

Figure 1




Figure 2





Figure 3

